BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26278546)

  • 1. Synergism of Curcumin and Cytarabine in the Down Regulation of Multi-Drug Resistance Genes in Acute Myeloid Leukemia.
    Shah K; Mirza S; Desai U; Jain N; Rawal R
    Anticancer Agents Med Chem; 2016; 16(1):128-35. PubMed ID: 26278546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
    Nasilowska-Adamska B; Solarska I; Paluszewska M; Malinowska I; Jedrzejczak WW; Warzocha K
    Ann Hematol; 2014 Apr; 93(4):577-93. PubMed ID: 24030729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
    Stam RW; van den Heuvel-Eibrink MM; den Boer ML; Ebus ME; Janka-Schaub GE; Allen JD; Pieters R
    Leukemia; 2004 Jan; 18(1):78-83. PubMed ID: 14574327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
    Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
    Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
    Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
    Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
    Pérez-Tomás R
    Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
    Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
    J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.
    Valera ET; Scrideli CA; Queiroz RG; Mori BM; Tone LG
    Sao Paulo Med J; 2004 Jul; 122(4):166-71. PubMed ID: 15543372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells.
    Lopes-Rodrigues V; Oliveira A; Correia-da-Silva M; Pinto M; Lima RT; Sousa E; Vasconcelos MH
    Bioorg Med Chem; 2017 Jan; 25(2):581-596. PubMed ID: 27908756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytarabine-Resistant
    Ko YC; Hu CY; Liu ZH; Tien HF; Ou DL; Chien HF; Lin LI
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
    Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
    Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of SCN5A overcomes ABC transporter-mediated multidrug resistance in acute myeloid leukemia through promoting apoptosis.
    Xu K; Zhuang XX; Shi XW
    Expert Rev Hematol; 2024; 17(1-3):87-94. PubMed ID: 38230679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mechanisms of drug resistance in leukemia.
    Ross DD
    Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
    Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
    Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-Treatments of Edible Curcumin from Turmeric Rhizomes and Chemotherapeutic Drugs on Cytotoxicity and FLT3 Protein Expression in Leukemic Stem Cells.
    Chueahongthong F; Tima S; Chiampanichayakul S; Berkland C; Anuchapreeda S
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    He Y; Sun L; Xu Y; Fu L; Li Y; Bao X; Fu H; Xie C; Lou L
    Cancer Lett; 2018 Apr; 420():49-59. PubMed ID: 29409989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.